eli lilly glp 1 pipeline More options=cost will drop! Why? Because competition. , Currently we have a monopoly from and Novo. But as you can see in the graphic, 7 other pharmaceuticals are working on their own GLP-1 Therapies Transform Obesity Landscape,

Physiological adaptations to weight loss and factors favouring weight regain

July 2024: A new study, published on July 3, 2024, indicates patients taking semaglutide such as Wegovy may face an increased risk of serious eye injuries, including nonarteritic anterior ischemic optic neuropathy (NAION)

Frequently Asked Questions Why are there two different protocols for the same drug

to treat obesity: Wegovy, Saxenda and Zepbound Emerging Marketplace Trends The GLP-1 market continues to be dynamic with five key emerging trends that employers and other stakeholders should consider, as they make actions that align with their coverage philosophy and population needs

Here, GLP-1RAs are one exciting option [28]